Kisqali
Novartis Sees Steady Q3 Pluvicto Sales Growth as it Readies to Triple Eligible Population in 2025
Premium
The Swiss drugmaker is gearing up to meet a surge in patient demand for the radiopharmaceutical if the FDA approves it in an earlier-line prostate cancer setting.
CHMP Recommends Approving Kisqali as Adjuvant Treatment for Early-Stage HER2-Negative Breast Cancer
The European Commission is expected to make a decision on Kisqali's approval in this setting in the next two months.
FDA Approves Novartis' Kisqali as Adjuvant Treatment for Early-Stage HER2-Negative Breast Cancer
The drug is approved in combination with an aromatase inhibitor as adjuvant therapy for breast cancer patients at high risk of recurrence.
Growth of the prostate cancer radiopharmaceutical was exponential following approval, but has now settled, leading Novartis to ramp up promotional efforts.
Researchers call for more data sharing from single-cell RNA sequencing studies to help validate machine learning precision medicine tools.